Curtis E. Haas, PharmD, FCCP, BCPS

Director of PharmacyCurtis Haas

Education: B.S., Albany College of Pharmacy; PharmD, State University of New York at Buffalo.

Certification: Pharmacotherapy, 1993 to present.

Faculty Appointments: School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo (Clinical Assistant Professor (Adjunct), Department of Surgery (current); Associate Professor of Pharmacy Practice; and Adjunct Associate Professor of Pharmacy Practice), 2000 – present; Clinical Assistant Professor (Adjunct), Department of Medicine School of Medicine and Dentistry, University of Rochester; Professor (Adjunct), Wegman’s School of Pharmacy, St. John Fisher College. 

Professional Affiliations: Current Member: American College of Clinical Pharmacy, Society of Critical Care Medicine, New York State Chapter of the American College of Clinical Pharmacy and Specialty Council for Pharmacotherapy, Board of Pharmaceutical Specialties. President-Elect, American College of Clinical Pharmacy.  Elected (National Election) to a three year term as a Presidential officer from 2011-2014. Chair, Task Force on Acute Care Pharmacy Practice Model, American College of Clinical Pharmacy; Regent, Board of Regents, American College of Clinical Pharmacy; Member, Research Subcommittee.  Clinical Pharmacy and Pharmacology Section, Society of Critical Care Medicine; Committee for Research Agenda, ACCP Research Institute, American College of Clinical Pharmacy; American Association of Colleges of Pharmacy; Member, Grant Review Committee, Clinical Pharmacy and Pharmacology Section, Society of Critical Care Medicine; Writing Committee, End of Life Care Guidelines in the ICU Society of Critical Care Medicine; Program Committee, Spring Meeting New York State Chapter of the American College of Clinical Pharmacy; Chair, Critical Care Practice and Research Network American College of Clinical Pharmacy; Frontier’s Fund Campaign PRN Coordinating Committee American College of Clinical Pharmacy; Frontier’s Fund Campaign PRN Coordinating Committee American College of Clinical Pharmacy; Chair-Elect, Critical Care Practice and Research Network American College of Clinical Pharmacy; Secretary-Treasurer, Critical Care Practice and Research Network American College of Clinical Pharmacy; Program Committee, 2003 ACCP Spring Practice and Research Forum American College of Clinical Pharmacy; Program Committee, Fall Meeting New York State Chapter of the American College of Clinical Pharmacy; Chair, Chapter Affairs Task Force American College of Clinical Pharmacy; President, New York State Chapter of the American College of Clinical Pharmacy; Secretary-Treasurer, New York State Chapter of the American College of Clinical Pharmacy; Member, American Society of Hospital Pharmacists; Chairman, Program Committee New York State Chapter of the American College of Clinical Pharmacy; Professional Affairs Committee – Clinical Subcommittee New York State Council of Hospital Pharmacists.

Publications: Peer-Reviewed Publications: Erstad BL, Haas CE, O’Keefe T, Hokula CA, Parrinello K, Theodorou AA. Interdisciplinary patient care in the intensive care unit: Focus on the pharmacist. Pharmacotherapy 2011;31(2):128-37; Erstad BL, Brophy GM, Martin SJ, Haas CE, Devlin JW, Welage LS, Dager WE. Key articles and guidelines relative to intensive care unit pharmacotherapy: 2009 Update. Pharmacotherapy 2009;29:1228-69; Nelsen JL, Haas CE, Habtemariam B, Kaufman DC, Partridge A, Welle S, Forrest A. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med 2008;23:184-94; Truog RD, Campbell ML, Curtis JR, Haas CE, Luce JM, Rubenfeld GD, Rushton CH, Kaufman DC. Recommendations for the end-of-life care in the intensive care unit: A consensus statement by the American Academy of Critical Care Medicine. Crit Care Med 2008;36:953-63; Raghavendran K, Wang J, Bellber C, Brunton K, Misra S, Berbary E, Haas CE. Predictive value of sputum gram stain for the determination of appropriate antibiotic therapy for VAP. J Trauma 2007;62:1377-82; Haas CE, Brazeau D, Cloen D, Booker BM, Frerichs V, Zaranek C, Frye RF, Kufel T. Cytochrome P-450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. Eur J Clin Pharmacol 2005;61:583-93.  On-line publication available at: http://dx.doi.org/10.1007/s00228-005-0971-0 ; Haas CE, Nelsen JL, Raghavendran K, Mihalko W, Beres J, Ma Q, Forrest A. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005;59:1336-44; LeBlanc JM, Haas CE, Vicente G, Beres J, Colon LA. Evaluation of lacrimal fluid as an alternative for monitoring glucose in critically ill patients. Intensive Care Med 2005;31:1442-5.  On-line publication available at:  http://dx.doi.org/101007/s00134-005-2747-5 ; Frerichs VA, Hagler CE, Haas CE. Analysis of omperazole, midazolam and hydroxyl-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;824:71-80; Haas CE, Lin L, Cloen D, Kufel T, Moon R, Frerichs V. Transdermal absorption of omeprazole in healthy volunteers. J Am Pharm Assoc 2005;45:473-8; Erstad BL, Martin SJ, Brophy GM, Haas CE, Jacobi J, Welage LS, Thomas MC. Key articles and guidelines relative to intensive care unit pharmacology – 2004. Pharmacotherapy 2005;25:585-610; Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John’s Wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508-14; Haas CE, LeBlanc JM. Acute Post-operative Hypertension: A review of therapeutic options.  Am J Health-Sys Pharm 2004;61:1661-75; Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by hypericum perforatum. Blood 2004;104:1229-30; Smith PF, Kearney BP, Liaw S, Bullock JM, Cloen D, Haas CE, Yale K, Booker BM, Berenson CS, Coakley DF, Flaherty JF.  Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S- methadone.  Pharmacotherapy 2004;24:970-7; Haas CE, Kaufman DC, Jones CE, Burstein AH, Reiss W. Cytochrome P-450 3A4 activity following surgical stress. Critical Care Medicine 2003;31:1338-46; Haas CE, Magram Y, Mishra A. Rhabdomyolysis and acute renal failure following an ethanol and diphenhydramine overdose. Ann Pharmacother 2003;37:538-42; Reiss RA, Haas CE, Griffis DL, Porter B, Tara MA. Point-of-care versus laboratory methods for monitoring newly anticoagulated patients.  Pharmacotherapy 2002;22:677-685; Haas CE, Kaufman DC, DiCenzo RC. Effects of metronidazole on hepatic CYP3A4 activity. Pharmacotherapy 2001;21(10):1192-1195; Kaufman DC, Haas CE, Spencer S, Veverbrants E. Adjustment of nutrition support with continuous hemodiafiltration in a critically ill patient. Nutrition in Clinical Practice 1999,14:120-123; Kaufman DC, Haas CE, Edinger R, Hollick G. Antibiotic Susceptibility in the surgical intensive care unit compared with the hospital-wide antibiogram. Archives of Surgery 1998;133:1041-5; Doak KK, Haas CE, Dunnigan KJ, et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy 1998;18:637-45; Reiss RA, Haas CE, Karki SD, Gumbiner B, Welle SL, Carson SW. Lithium pharmacokinetics in the obese. Clin Pharmacol Therap 1994;55:392-8; Altavela JL, Haas CE, Nowak DR, Powers JM, Gacioch GM. Clinical response to intravenous nitroglycerin infused through polyethylene or polyvinyl chloride tubing. Am J Hosp Pharm 1994;51:490-4; Haas CE, Nowak DR, Mabb WA. Intravenous nitroglycerin administered using a standard polyvinyl chloride set reduces cost without affecting clinical response. Am J Hosp Pharm 1992,49(5):1135-7; Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990;34(9):1637-41; Haas CE. Nifedipine - Poor absorption after sublingual administration. NY State J Pharm 1989;9:10-1; Haas CE, Paladino JA, DiBona JR. Effect of a preprinted chart note on appropriate cefazolin prescribing. Am J Hosp Pharm 1986;43:1754-6.

Book chapters, editorials, commentary: Haas CE. Monitoring anticoagulation therapy in the critically ill. Critical Connections 2008; 7(2):10-11; Haas CE, Forrest A. Pharmacokinetic and pharmacodynamic research in the ICU:  An unmet need (Editorial). Crit Care Med 2006;34:1831-3; Haas CE, Nelsen JL. Drug-Cytokine Interactions. IN: Piscitelli SC, Rodvold KA, Eds. Drug Interactions in Infectious Diseases, 2nd Edition. Humana Press, Totawa, NJ, 2005:431-61; Haas CE, LeBlanc JM. Chapter 8. Critical Care Pharmacologic Principles: Vasoactive Drugs. IN: Papadakos PJ, Szalados JE, Eds. Critical Care. The Requisites in Anesthesiology, Mosby, Inc. Philadelphia. 2005:89-105; Haas CE. Chapter 11. Drug-Cytokine Interactions. IN: Piscitelli SC, Rodvold KA, Eds. Drug Interactions in Infectious Diseases. Humana Press, Totawa, NJ, 2001:287-310.

Awards & Honors: Presidential Citation, Society of Critical Care Medicine; Presidential Citation, Society of Critical Care Medicine; Teaching Innovation Award, University at Buffalo; Educator of the Year, New York State Chapter of the American College of Clinical Pharmacy; Fellow (FCCP), American College of Clinical Pharmacy; Teacher of the Year, School of Pharmacy and Pharmaceutical Sciences University at Buffalo; Faculty Service Award, Phi Lambda Sigma, Beta Omicron Chapter, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo; Pharmacotherapy Clinical Research Award, American College of Clinical Pharmacy; Clinical Practitioner of the Year, New York State Chapter of the American College of Clinical Pharmacy; Excellence in Classroom Teaching Award, Physician’s Assistant Program, Rochester Institute of Technology; Classroom Teacher of the Year Award, Doctor of Pharmacy Program, University at Buffalo.

Email: curtis_haas@urmc.rochester.edu

Contact Us

Strong Memorial Hospital Outpatient Pharmacy
(585) 275-4931

Highland South Wedge Pharmacy
(585) 279-4790

Strong Ties Outpatient Pharmacy
(585) 279-4950

Infectious Disease Clinic Pharmacy
(585) 275-6272

URMC Employee Pharmacy
(585) 276-3900

URMC Specialty Pharmacy
(585) 273-4767 Or
(855) 340-4767

Highland Pharmacy at Jordan Health Center
(585) 423-5802

James P. Wilmot Cancer Center Pharmacy
(585) 275-5170

Investigational Drug Studies
(585) 275-6153

Summary of Residency Program

Starting Date: July 1

Type/Duration: 12 month/full-time

Application Deadline: January 10

Interview Required: Yes

Presentation Required: Yes

Curriculum Vitae Required: Yes

College Transcripts Required: Yes

Letters of Recommendation: Three